Here’s How EUA for Celltrion Affects Indonesia’s COVID-19 Response
![army fighting coronavirus](https://cdn1.katadata.co.id/media/dinsights/images/thumb/2021/07/01/2021_07_01-22_41_09_0d822b817b9240919476163e00c517a7_620x413_thumb.jpg)
Celltrion, a drug manufacturer from South Korea, claims to have secured an emergency use authorization (EUA) from the Food and Drug Monitoring Agency (BPOM) for a drug called Regkirona. The Korea Biomedical Review reported that the permit was out on July 17, 2021. Regkirona reportedly showed efficacy in treating adult COVID-19 patients with mild and moderate symptoms.
The company hopes that the Regkirona antibody treatment can curb COVID-19 transmissions in Indonesia. Celltrion has confirmed its efficacy in neutralizing the Delta variant of COVID-19 through animal tests. "Regkirona has proven its efficacy through global clinical and quality data. The authorization is expected to speed up Regkirona’s export negotiations," a company’s official said.